PMCF Study of Precise Pro Rx for Carotid Artery Disease (REAL-PRECISE)
Post Market Clinical Follow-up Study of the Precise Pro Rx Nitinol Stent System in the Treatment of Carotid Artery Disease (REAL-PRECISE)
Sponsor: Cordis US Corp.
A observational or N/A phase clinical study on Carotid Artery Stenosis, this trial is completed. The trial is conducted by Cordis US Corp. and has accumulated 4 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
4 versions recorded-
Mar 2026 — Present [monthly]
Completed
Status: Enrolling By Invitation → Completed
-
Feb 2026 — Mar 2026 [monthly]
Enrolling By Invitation
Status: Not Yet Recruiting → Enrolling By Invitation
-
Dec 2025 — Feb 2026 [monthly]
Not Yet Recruiting
-
Nov 2025 — Dec 2025 [monthly]
Not Yet Recruiting
First recorded
Oct 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cordis US Corp.
- Rede Optimus Hospitalar SA
For direct contact, visit the study record on ClinicalTrials.gov .